Advancing Tobacco Use Treatment for African American Smokers (KIS-IV)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02360631|
Recruitment Status : Active, not recruiting
First Posted : February 10, 2015
Last Update Posted : October 9, 2018
|Condition or disease||Intervention/treatment||Phase|
|Smoking Cessation||Drug: Chantix Drug: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||500 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Advancing Tobacco Use Treatment for African American Smokers|
|Study Start Date :||July 2015|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
Experimental: Chantix (varenicline)
Participants will receive 1mg pills to take twice a day for 12 weeks.
A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.
Other Name: Varenicline
Placebo Comparator: Placebo
Participants will receive a placebo pill to take twice a day for 12 weeks.
Health education counseling will be provided to all participants.
- Smoking Abstinence [ Time Frame: Month 6 ]Biochemically verified 7-day point prevalence abstinence defined as smoking zero cigarettes at Month 6 visit
- Smoking Abstinence [ Time Frame: Week 12 ]Biochemically verified 7-day point prevalence abstinence defined as smoking zero cigarettes at Week 12 visit
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02360631
|United States, Kansas|
|University of Kansas Medical Center|
|Kansas City, Kansas, United States, 66160|
|United States, Missouri|
|Swope Health Central|
|Kansas City, Missouri, United States, 64130|
|Principal Investigator:||Lisa Sanderson Cox, PhD||University of Kansas Medical Center|